Today, CRISPR/Cas9 has emerged as the genome editing method of choice in research, medicine, and biotechnology. Compared to other gene editing technologies (e.g. ZFNs and TALENs), it is simpler to re-engineer, easier to use, has broad versatility, and can target multiple sites. One essential factor enabling to explore the full CRISPR potential is efficient delivery of its components into physiologically relevant cell types.
Many renowned scientists are already using Lonza’s non-viral NucleofectorTM Technology for delivering CRISPR plasmids or RNPs efficiently into various cell types. In this webinar, we discuss best practices to achieve optimal delivery results.
Topics:
- Understand the basic principle of CRISPR-based genome editing and its potential applications or modes of use
- Learn how to achieve efficient delivery into hard-to-transfect cell lines, primary cells or stem cells
- Get tips and tricks for using the NucleofectorTM Technology as a powerful non-viral delivery method